Small-molecule activators of STING-signaling as novel adjuvants for flavivirus vaccines

STING 信号小分子激活剂作为黄病毒疫苗的新型佐剂

• 批准号: 10027069
• 负责人: JAY NELSON
• 金额: $ 206.12万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2020-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10027069
• 关键词: Adaptive Immune System; Adjuvant; Animal Model; Antigens; Award; B-Lymphocytes; Cells; Chikungunya virus; Contractor; FDA approved; Flavivirus; Human; Immunologic Memory; Innate Immune System; Libraries; Pharmaceutical Chemistry; Preventive vaccine; Research; Signal Pathway; Signal Transduction; T-Lymphocyte; Testing; Vaccines; Zika Virus; base; human disease; lead optimization; novel; pathogen; response; small molecule; therapeutic vaccine; vaccine efficacy

The contractor will identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research performed under this award will contribute to the pipeline of new adjuvant leads that either: (a) exploit the natural capacity of the innate immune system to initiate and sustain effective T and B cell responses and to induce long term immune memory, or (b) act directly on cells of the adaptive immune system to enhance their response to pathogen-derived antigens. Studies include testing of adjuvant candidates with experimental or FDA approved preventative or therapeutic vaccines in relevant animal models to determine the potential efficacy of the vaccine against one or more pathogens relevant to human disease.

承包商将确定可用于增强人类疫苗效力的新型候选佐剂。在该奖项下进行的研究将有助于新佐剂的管道，导致：（a）利用先天免疫系统的天然能力，以启动和维持有效的T和B细胞反应，并诱导长期免疫记忆，或（B）直接作用于适应性免疫系统的细胞，以增强其对病原体衍生抗原的反应。 研究包括在相关动物模型中使用实验性或FDA批准的预防性或治疗性疫苗测试候选佐剂，以确定疫苗针对一种或多种与人类疾病相关的病原体的潜在功效。